GL Pharm Tech Corp. (KOSDAQ:204840)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,084.00
+14.00 (1.31%)
At close: Mar 27, 2026
Market Cap84.06B +13.2%
Revenue (ttm)35.27B +37.7%
Net Income12.49M
EPSn/a
Shares Out77.55M
PE Ratio6,730.99
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume158,642
Average Volume248,313
Open1,061.00
Previous Close1,070.00
Day's Range1,047.00 - 1,090.00
52-Week Range963.00 - 1,844.00
Beta0.60
RSI50.16
Earnings DateApr 1, 2026

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further... [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 33
Stock Exchange KOSDAQ
Ticker Symbol 204840
Full Company Profile

Financial Performance

In 2024, GL Pharm Tech's revenue was 26.05 billion, an increase of 0.06% compared to the previous year's 26.03 billion. Losses were -2.34 billion, -37.64% less than in 2023.

Financial Statements